Serum protein binding kinetics of phenytoin in monotherapy patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 5, 1998, Pages 361-365

  Kodama, Hirofumi ^a   Kodama, Yasuo ^b   Shinozawa, Shinya ^a   Kanemaru, Reizo ^c   Todaka, Kazunari ^a   Mitsuyama, Yoshio ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Kanemaru Neurosurgery Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; PLASMA PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BINDING KINETICS; BINDING SITE; CHILD; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EPILEPSY; ETHNIC DIFFERENCE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PLASMA PROTEIN BINDING;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PHENYTOIN; PROTEIN BINDING;

EID: 0031674054     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00173.x     Document Type: Article

References (26)

1. Brodie MJ. (1990) Established anticonvulsants and treatment of refractory epilepsy. Lancet, 336, 350-354.
2. Richens A. (1979) Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics, 4, 153-169.
3. Finn AL. (1983) Anticonvulsants. In: Mungall DR. Applied Clinical Pharmacokinetics, New York: Raven Press, pp. 103-126.
4. Lund L, Berlin A, Lunde PKM. (1972) Plasma protein binding of diphenylhydantoin in patients with epilepsy. Clinical Pharmacology and Therapeutics, 13, 196-200.
5. Theodore WH, Yu L, Plice B, Yonekawa W, Porter RJ, Kapetanovic I, Moore H, Kupferberg H. (1985) The clinical value of free phenytoin levels. Annals of Neurology, 18, 90-93.
6. Paterson GM, McLean S, Von Witt RJ, Millingen KS. (1985) Audit of a monitoring service for free phenytoin. British Journal of Clinical Pharmacology, 19, 693-697.
7. Brodie MJ, Muir SE, Agnew E, Macphee GJA, Void G, Teasdale E, Macpherson P. (1985) Protein binding and CSF penetration of phenytoin following acute oral dosing in man. British Journal of Clinical Pharmacology, 19, 161-168.
8. Booker HE, Darcey B. (1973) Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia, 14, 177-184.
9. Allison TB, Comstock TJ. (1988) Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia. Therapeutic Drug Monitoring, 10, 376-381.
10. Lecomte M, Zini R, d'Athis P, Tillement JP. (1979) Phenytoin binding to human albumin. European Journal of Drug Metabolism and Pharmacokinetics, 1, 23-28.
11. Odar-Cederlöf I, Borgå O. (1976) Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clinical Pharmacology and Therapeutics, 20, 36-47.
12. Kinniburgh DW, Boyd ND. (1981) Phenytoin binding to partially purified albumin in renal disease. Clinical Pharmacology and Therapeutics, 29, 203-210.
13. Lentner C. (1984) Geigy Scientific Tables, 8th edn. Vol. 3. Ciba-Geigy, Basle, pp. 65-204.
14. Hayes MJ, Langman MJS, Short AH. (1975) Changes in drug metabolism with increasing age: 2. Phenytoin clearance and protein binding. British Journal of Clinical Pharmacology, 2, 73-79.
15. Kodama Y, Koike Y, Kimoto H, Yasunaga F, Takeyama M, Teraoka I, Fujii I. (1992) Binding parameters of valproic acid to serum protein in healthy adults at steady state. Therapeutic Drug Monitoring, 14, 55-60.
16. Kodama Y, Tsutsumi K, Teraoka I, Fujii I, Takeyama M. (1993) Effect of unbound clearance on binding parameters of valproic acid to serum proteins. Journal of Clinical Pharmacology, 33, 130-135.
17. Triedman HM, Fishman RA, Yahr MD. (1960) Determination of plasma and cerebrospinal fluid levels of Dilantin in a human. Transactions of the American Neurological Association, 85, 166-170.
18. Buchanan RA, Kinkel AW, Goulet JR, Smith TC. (1972) The metabolism of diphenylhydantoin (Dilantin) following once-daily administration. Neurology, 22, 126-130.
19. Ohshima T, Johno I, Kitazawa S. (1988) Comparative evaluation of microultrafiltration devices for determination of protein binding. Therapeutic Drug Monitoring, 10, 310-315.
20. Brørs O, Jacobsen S. (1985) pH Liability in serum during equilibrium dialysis. British Journal of Clinical Pharmacology, 20, 85-88.
21. Wilkinson L. (1988) SYSTAT: the System for Statistics. SYSTAT Inc., Evanston.
22. Anderson GD, Gidal BE, Hendryx RJ, Awan AB, Ternkin NR, Wilensky AJ, Winn HR. (1994) Decreased plasma protein binding of valproate in patients with acute head trauma. British Journal of Clinical Pharmacology, 37, 559-562.
23. Monks A, Boobis S, Wadsworth J, Richens A. (1978) Plasma protein binding interaction between phenytoin and valproic acid in vitro. British Journal of Clinical Pharmacology, 6, 487-492.
24. Barre J, Didey F, Delion F, Tillement JP. (1988) Problems in therapeutic drug monitoring: free drug level monitoring. Therapeutic Drug Monitoring, 10, 133-143.
25. Mcleod DC. (1988) SI units in drug therapeutics. Drug Intelligence and Clinical Pharmacy, 22, 990-993.
26. Pospíšil J, Perlík F. (1992) Binding parameters of phenytoin during monotherapy and polytherapy. International Journal of Clinical Pharmacology Therapy and Toxicology, 30, 24-28.